- Capital Clubhouse Named Finalist in DC Congresswoman Eleanor Holmes Norton’s Community Project Funding Initiative (April 28, 2021)
- In Bloomberg Law, Attorneys Analyze Potential Costs of Reshoring Pharmaceutical Manufacturing
(April 9, 2021)
- Event: Navigating Life Sciences M&A Under the Biden Administration | Drug Pricing & Antitrust Considerations (March 25, 2021)
- What the U.S. Federal Government Might Learn from States About Regulating Drug Pricing (March 24, 2021)
- Podcast: CMMI Program Delays and Suspensions—Recommended Next Steps (March 18, 2021)
- In Law360, Kirsten Mayer Addresses Kickback Liability Under False Claims Act During Coronavirus Pandemic (March 15, 2021)
- Law360 Profiles Tara Fisher on Guiding Novavax in Pursuit of COVID-19 Vaccine (March 11, 2021)
- In Law360, Health Care Attorneys Analyze Information Blocking Rule Opportunities for Clinical Research (March 9, 2021)
- Event: Outlook 2021 – Washington, D.C. Updates and Insights on Life Sciences and Health Care (February 25, 2021)
- In Law360, Margaux Hall Examines Drug Commercialization and Market Access Strategies in Light of Drug Pricing Regulatory Uncertainty Under the Biden Administration
(February 16, 2021)
- 2022 Medicare Advantage and Part D Final Rule Includes Update to Star Ratings System and Implementing Coverage and Transparency Measures (February 5, 2021)
-
Medicare Expands Coverage of “Breakthrough” Medical Devices and Codifies “Reasonable and Necessary” Standard
(January 21, 2021)
- Health Care Co-Chairs Address Key Issues Facing Health Payers in 2021
(January 8, 2021)
- In Law360, Tom Bulleit Analyzes 2021 Health Policies Under the Biden Administration (January 5, 2021)
- In Law360, Attorneys Evaluate 2021 IPO Market (January 5, 2021)
- The 2020 Election and Health Care (December 15, 2020)
- In Bloomberg Law, Tom Bulleit Discusses New “Stark” and Anti-Kickback Rules for Value-Based Arrangements (November 25, 2020)
- In Law360, Health Care Attorneys Examine State Drug Pricing Reforms (November 25, 2020)
Cookie Settings
